Havrix

Havrix is a prescription‑only hepatitis A vaccine that contains inactivated hepatitis A virus adsorbed onto aluminium hydroxide and is supplied as an injectable solution. The product is manufactured for the European market and is administered by intramuscular injection to stimulate active immunity against hepatitis A virus in adults and children. It belongs to the inactivated viral vaccine class and is used for prophylaxis of hepatitis A infection.

Havrix is indicated for the prevention of hepatitis A infection in individuals who are at risk of exposure.

- Travel to regions where hepatitis A is endemic or where outbreaks have been reported. - Occupational exposure for laboratory personnel handling hepatitis A virus. - Household contacts of persons with confirmed hepatitis A infection. - Patients with chronic liver disease who require additional protection. - Individuals seeking immunity before receiving blood products or organ transplants.

Following intramuscular administration, Havrix may be associated with a range of transient reactions. These events typically appear within a few days after vaccination and resolve without specific treatment. Medical evaluation is advised if they persist.

Common: - Pain, redness or swelling at the injection site - Mild fever - Headache - Fatigue - Muscle aches - Nausea or gastrointestinal discomfort

Serious: - Severe allergic reaction (anaphylaxis) - Guillain‑Barré syndrome (very rare) - High fever lasting more than 24 hours - Seizures (rare) - Neurological symptoms such as weakness or numbness

Healthcare providers should assess individual risk factors and medical history before administering Havrix to ensure safe use.

- Defer vaccination in persons with known severe allergy to any vaccine component, including aluminium salts. - Postpone administration in individuals experiencing moderate or severe acute illness. - Consider delaying the vaccine in pregnant women; safety data are limited. - Observe patients for at least 15 minutes after injection to monitor for immediate hypersensitivity. - Immunocompromised patients may have a reduced antibody response; discuss alternative protection strategies. - Do not administer concurrently with other live vaccines; separate by at least 4 weeks.

Havrix does not have many documented drug‑drug interactions, but certain co‑administered agents may require attention.

Avoid: - Concurrent administration with other injectable vaccines containing aluminium adjuvants, which may increase local reactogenicity. - Live viral vaccines given within 4 weeks before or after Havrix, to avoid interference with immune response.

Use with caution: - Immunosuppressive therapies (e.g., corticosteroids, chemotherapy) that could diminish vaccine efficacy. - Antipyretics such as acetaminophen or ibuprofen taken prophylactically, which might blunt antibody production. - Blood products administered shortly before or after vaccination, as they may affect seroconversion.